European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH (non-alcoholic steatohepatitis) transition to inform early prevention and treatment strategies

Descripción del proyecto

DE EN ES FR IT PL

Biomarcadores para la esteatosis hepática no alcohólica

La esteatosis hepática no alcohólica (EHNA) es un enfermedad compleja que conlleva la acumulación de grasa en el hígado que promueve la inflamación hepática. Es difícil de diagnosticar y tratar porque aún se desconocen los mecanismos moleculares subyacentes. El objetivo del proyecto halt-RONIN, financiado con fondos europeos, es investigar el desarrollo de la EHNA en personas sanas. El consorcio desarrollará modelos «in vitro» e «in vivo» y, junto con datos clínicos de pacientes, descubrirá nuevos biomarcadores y dianas moleculares específicas. Se espera que los resultados ayuden al diagnóstico de la EHNA, al desarrollo de intervenciones modificadoras de la enfermedad y la elaboración de directrices de prevención.

Objetivo

Non-alcoholic fatty liver disease (NAFLD) is a multifactorial chronic inflammatory disease that is prevalent in 1 of 4 individuals with a significant personal, socioeconomic and healthcare burden, especially at the later, more severe inflammatory stage of disease - non-alcoholic steatohepatitis (NASH). Despite the severe negative impact of the disease on society, NAFLD remains difficult to diagnose and treat. Additionally, the molecular mechanisms underlying the transition from health to fatty liver to NASH remain poorly understood due to the lack of models that faithfully reflect the complexity of human disease. Hence, Halt-RONIN aims to uncover the early triggers of disease initiation and complex mechanistic drivers of disease progression by implementing a systems biology approach with integrative disease modelling resulting in opportunities for the improvement of the existing detection methods, providing a blueprint to inform personalized intervention strategies and drug discovery for NAFLD. To achieve this goal, Halt-RONIN will combine experimental data from advanced in vitro and in vivo models with multimodal data from extensive human NAFLD cohorts and biobanks and use in silico machine learning approaches, to discover new biomarkers and molecular targets specific to each stage of the health-to-disease transition. By validating preclinical experimental findings with real-world data, RONIN will allow for the discovery of novel biomarkers and molecular targets that are specific to the individual patient’s pathology. Consequently, healthcare professionals will gain the tools and knowledge required to diagnose and establish guidelines for the prevention and treatment of inflammation-driven health to disease. As such, in the long-term RONIN will decrease the number of NAFL patients who progress into NASH and provide disease-modifying strategies to improve patient outcomes.

Ámbito científico

Palabras clave

Programa(s)

Tema(s)

Convocatoria de propuestas

HORIZON-HLTH-2022-STAYHLTH-02

Consulte otros proyectos de esta convocatoria

Régimen de financiación

HORIZON-RIA - HORIZON Research and Innovation Actions

Coordinador

UNIVERSIDAD COMPLUTENSE DE MADRID
Aportación neta de la UEn
€ 815 651,53
Dirección
AVENIDA DE SENECA 2
28040 Madrid
España

Ver en el mapa
Región
Comunidad de Madrid Comunidad de Madrid Madrid
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 815 651,53

Participantes (19)

Socios (3)

Compartir esta página

Descargar

Última actualización: 28 Noviembre 2022

Mi folleto

Permalink: https://cordis.europa.eu/project/id/101095679/es

European Union, 2024